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Intellectual property rights (IPR) in biotechnology are having a dramatic nega-
tive effect on the progress of nonprofit research. Although patent policy and 
law intend to facilitate research progress, the current practice has led to many 
barriers in access and use of genetic materials and DNA technology. Such bar-
riers restrict the free exchange of information and threaten the health of our 
nation’s scientific enterprise. Policies related to patents and licensing are increas-
ing the cost of research at a time when funds for research are being reduced.
We wish to discuss some current issues related to research in biotechnology 
carried out in academic institutions, particularly land-grant universities, and 
the rapidly changing roles of scientists in relation to intellectual property and 
industry. The rapid changes in the arena of intellectual property are more acute 
in the area of biotechnology, which is still in the early stages of development and 
where many issues are not yet well defined. Further consideration is needed of 
the costs and benefits of current patent policy and law. Problematic examples are 
discussed. Some provision (amendment or extension of law) should be made to 
foster the conduct of basic research in universities and other nonprofit research 
institutions, and to some extent provide an exemption from the law that governs 
commercial research and development.
BiotechnologyandtheLandGrantUniversities
Life is not simple for an academic institution engaged in biotechnology research 
today. As land-grant universities attempt to redefine their mission relative to 
society, conflicts arise over the interrelated roles of research and protection of
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intellectual property. Even as intellectual property rights are pursued more 
vigorously by universities, the heart of the research enterprise is being 
constrained by the protection of intellectual property owned by others. Industry 
can invest much more in obtaining and defending intellectual property than 
universities can. As the law stands, and as current policies are enforced, it is 
unlikely that the balance will tilt in favor of the universities.
In the last two decades, universities have redefined their approach to tech-
nology transfer. The universities have simultaneously viewed it as a channel 
for added revenue and as a vehicle for ensuring that the discoveries of the 
laboratory are transformed into goods and services beneficial to society. Aggres-
sive businesslike pursuit of protection for intellectual property generated at a 
university (which can then be licensed to a company for development) has led 
to the erosion of an apparent special status for universities as the home of ex-
clusively “philosophical” activities. With this change, university efforts actually 
receive no “research exemption” and university faculty have no special right to 
explore patented inventions or to utilize protected findings or technologies.
Constraints on the research enterprise have significant implications for the 
well-being of society. When researchers are restricted in attempts to extend our 
knowledge of the world around us, society pays a cost of lost innovation, which 
is crucial for economic development and the wellbeing of our citizens. It is of 
particular concern when the research is carried out with federal funds and the 
cost of the research is either greatly increased, or it becomes impossible to carry 
out the research at all.
The traditional relationship of scientists and their funding agencies has 
changed. Since the Bayh-Dole Act of 1980, funding agencies have allowed 
intellectual property to be owned by the institution where the research was 
conducted. Generally, universities will retain ownership of patents even if the 
majority of the funding for a specific project comes from outside sources. 
Industry-funded research at universities usually requires some specific industry 
rights to licensing that ensures some potential or expressed degree of access 
to intellectual property resulting from the research. If a company obtains 
exclusive rights to license, they can have a great deal of control over subsequent 
technology based upon the patents. In many cases, related projects conducted 
by the same scientist are derived from public funding, often confounding the 
issue of who owns what.
IssuesofOwnership
Under appropriate conditions, the sequence of nucleotides that represents 
a gene may be patented. The patenting of genes must still satisfy criteria of 
novelty, utility and reduction to practice. Anonymous gene sequences with 
no knowledge of function are not sufficient for patent protection. It is not yet 
resolved to what extent similar sequences are covered by specific gene patents.
If a gene for a specific enzyme was patented, should that patent cover all genes
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encoding that function or only that specific sequence? Much of the variation 
between related genes for the same function could be significant and valuable. 
What if the gene was obtained from a related member of the same species that 
had a different sequence? What if the gene was from a distantly related species? 
Some principles of what constitutes “equivalence” for a particular gene remain 
to be resolved. The issue of equivalence is important because once a sequence 
of a gene of known function is made available through publication or through a 
public database. It is possible for a molecular biologist to obtain an equivalent 
gene from another individual of the same species or of a different species. The 
different species could be as distantly related as a plant and an animal.
Issues of ownership of genes have become more critical as more large-scale 
sequencing projects are carried out to identify genes from organisms for 
commercial application. Specific genes with potential application can then 
be patented which means that use of these genes could be removed from the 
public domain, and research into their potential applications could be curtailed.
It is common practice to use patents and licensing to protect some genes 
where commercial development is possible. Current procedures for obtaining 
use of licensed genes can be extremely cumbersome and expensive. In fact, 
negotiating agreements that allow universities to conduct research with genes 
owned by industry can delay research for years. Such delays are unreasonable 
when research objectives are noncommercial and are supported by federal 
funds. Similar situations arise for other DNA sequences used as promoters or 
vectors for transformation. In the past, constructs have been available with 
restrictions on distribution and potential commercial application, but without 
cost. This situation appears to be changing, and charges are being added to 
such agreements. A new promoter, highly expressed in plant cells, has recently 
been made available through a licensing agreement to individual university 
laboratories for $1500.
As individual genes have been patented, the question of patentability may be 
raised about genomic maps. The process of constructing gene maps is derived 
from genetic studies conducted before 1920, and is fundamentally unchanged, 
except for the new kinds of molecular markers and the computer software that 
greatly facilitates map construction. We know of no examples of the patenting 
of an entire genomic map. However, specific genetic markers on genomic maps 
have patent potential for specific purposes such as diagnosis. These genetic 
markers would also have utility for disease detection in humans, and in 
breeding of plants and animals. Once a specific marker is located that would 
predict resistance to a disease, for example, it would be relatively easy for a 
mapper to identify other markers that would be equivalent in their ability to 
predict resistance, but would bear no relationship to the original marker in 
sequence, only in genome location and linked to an allele of specific interest.
It remains to be resolved to what extent markers can be protected by patent, 
and whether such protection might extend to adjacent regions of the genome.
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A related issue to genomic mapping is the sequencing of entire genomes 
of specific organisms. The first entire sequence of a free living organism, the 
bacterium, Haemophilus influenzae Rd., has recently been completed. Such 
information could have industrial applications. However, the extent and utility 
of patentable information from genomic sequencing remains to be defined.
GenomicMappingusingPCR
New polymerase chain reaction (PCR)-based genomic marker technology 
(discussed below) has revolutionized genetic analysis for many species of 
plants and animals. This use of PCR was unanticipated. It represented a new 
application of PCR on a very much larger scale for individual laboratories than 
had been anticipated. Licensing of PCR has dramatically increased the cost of 
genomic mapping. The costs of licensing for this type of genetic analysis raise 
the cost of each reaction from several cents to about 30 cents a reaction. A 
typical mapping experiment can require tens of thousands of reactions, and a 
large experiment may involve a million reactions. Experiments that would have 
cost hundreds of dollars for materials instead now costs many thousands due 
to the licensing strategy for PCR. These greatly increased costs result from the 
patented process of PCR, and from the unusual status of the enzyme, Taq 
polymerase, used for the PCR reactions.
Taq polymerase has an unusual status as a reagent for molecular biology 
because its purchase from an approved source confers a license to practice PCR. 
As a result of this licensing strategy, the costs have placed an unanticipated 
burden upon laboratories exploring the large scale use of PCR for genomic 
mapping and genomic sequencing.
Taq polymerase is a heat-stable DNA polymerase purified from the thermo-
philic bacterium Thermus aquaticus. A process patent on PCR and the use of 
a natural enzyme for this process, Taq polymerase, (US Patent Nos. 4,889,818 
and 5,079,352) have been licensed to the research community by the holders of 
the patents (Hoffman-La Roche Co.) through the purchase of the enzyme from 
specific suppliers (licensed by Hoffman-La Roche), and through the purchase of 
equipment and accessories from The Perkin-Elmer Corporation. The worldwide 
research community is considered to be an important market for the licensing 
of the PCR process and for the sale of the enzyme. As a result of the patenting, 
licensing and pricing strategy, the cost of the enzyme is far more expensive than 
most other widely used, easily purified enzymes of nucleic acid metabolism, 
such as restriction enzymes.
Of the hundreds of enzymes used as reagents in molecular biology, few are 
restricted through their use in a patented process. Taq polymerase cannot be 
purified legally by individual investigators for use with PCR. Scientists who 
wish to practice PCR are required to purchase the enzyme and are prohibited 
from purifying the enzyme for their own use. The purification of the enzyme 
is relatively easy and would provide the enzyme at a fraction of the current 
commercial price.
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RAPD Markers
Randomly Amplified Polymorphic DNA (RAPD) markers, developed by DuPont 
Co. scientists and almost simultaneously at the California Institute of Biological 
Research in San Diego, provided a novel DNA marker technology for genomic 
mapping in plants and animals. The method was advantageous because it could 
be applied with no prior information and could be done using small amounts of 
DNA. The method was particularly useful for species with no history of genetic 
analysis or DNA sequencing. The cost of Taq polymerase has been the major 
barrier to the application of this technology to a number of new problems, for 
example, a large site adaptation study planned for loblolly pine that would re-
quire 1.5 million PCR reactions, making the research too expensive to undertake.
Recently, a new patent has been issued to DuPont that covers the use of 
RAPD markers. DuPont has licensed exclusive rights to the use of this marker 
technique for certain species to an Australian company, ForBio Ltd., which will 
license RAPD markers to individual laboratories at a specific charge for each 
RAPD reaction. RAPD reactions also use PCR and require licensed use of Taq 
polymerase. However, ForBio and DuPont have decided not to charge fees for 
research carried out in universities or government laboratories that “has no 
commercial purpose.” This distinction deserves consideration; it could set a 
precedent for protecting freedom of inquiry.
AlternativeMarkerTechnologies
The high cost of licensing both PCR and RAPD technology has stimulated 
interest in alternative methods. Several such methods are available, each with 
different advantages and disadvantages. These include microsatellites, amplified 
fragment length polymorphism (AFLP) or use of cDNA-amplified polymor-
phisms (CAPs) and others. All require PCR, except for the earlier methods of 
restriction fragment polymorphism (RFLP). RFLP methods are not well suited 
to large-scale experiments.
UnintendedNegativeEffects
For most if not all enzymes used in routine research in molecular biology, the 
cost of obtaining the enzyme from commercial sources is advantageous relative 
to the cost of producing enzyme in a research laboratory. The relative cost of 
production and the price of the product results in reasonable profit to the 
producers and savings in time to the purchasers. There is no incentive for 
infringement. The current circumstances surrounding the use and production 
of Taq polymerase are different. At a cost of a few thousand dollars, laboratories 
working on a small scale could, in short time, easily produce for their own 
research use what would cost millions of dollars through the current PCR/Taq 
polymerase licensing strategy. The ability to produce their own enzyme would 
allow some laboratories to conduct research that is essentially not affordable 
under current licensing requirements. Thus, the current environment could
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foster deliberate patent infringement to the detriment of both the patent system 
and the university research enterprise.
Advances in mapping technology based on PCR raise several issues that 
epitomize problems affecting the current national research effort and the future 
of publicly funded university-based research. There is no doubt that the 
invention of specific amplification of DNA through PCR has been one of the 
most significant new techniques in biotechnology. Current strategies of 
intellectual property protection and commercialization may impede or block 
research efforts, exacting a social cost. Proprietary constraints on the practice 
of PCR have three aspects: the practice of the invention, the specific enzyme 
used to practice the invention, and the equipment needed to practice. The 
patent holders have chosen to license the practice of PCR through the sale 
of enzyme and sale of equipment that can be used to practice PCR. In part 
because the large-scale application to mapping was unanticipated, the licensing 
strategy has had unintended negative effects on U.S. research, and related 
research worldwide.
Biotechnology arose from several decades of research based upon the free 
exchange of information and materials. Most research during these crucial 
formative years was “basic” and was supported by public funds or foundations. 
Little consideration was given to intellectual property, and new information 
was released and made available through publication or conferences. If many 
of the fundamental advances made during this time had been patented, it is 
unlikely that the field of biotechnology would have developed by this time. It 
is instructive to consider how the past 45 years of progress would have been 
constrained if each major discovery or new process was patented and licensed. 
Essentially no restrictions or licensing costs were placed on any processes or 
molecules involved in biosynthesis, in vitro synthetic processes, methods of 
purification, or products of these processes. These fundamentally important 
advances remain unconstrained today. The free exchange of information 
depended upon public funding, and a certain “culture” promoting free 
exchange in the conduct of research.
If a major shift occurs from public funding to industrial funding, and if 
current intellectual property protection strategies continue to be pursued, 
the nature of the university research enterprise related to biotechnology 
could change in dramatic ways. Industrial research is more likely to remain 
short-term in perspective and will focus upon practical applications and 
products for development rather than discoveries of general interest. Industry- 
driven research is more likely to be directed to produce patents rather than 
publications. Academic objectives of scholarly work are different from that of 
patents in purpose and standards of proof. One of the challenges to universities 
is the need to maintain the high standards of scholarship while pursuing 
patentable technology.
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Whatis  theCostofResearchNotDonH ?
The value of university research lies in the addition to the knowledge base 
of our society. New information and resultant technology drive economic 
development, maintains a competitive advantage for the nation as a whole and 
leads to a better informed and more productive citizenry. If wisely applied, such 
information should provide a basis for the conservation of natural resources 
and the ability to extend a higher living standard to our citizens and others 
throughout the world. Thus, there is an assumption that the benefits of research 
have high value. Yet, the inability to quantify such benefits and to predict when, 
how, and specifically to whom the benefits accrue means that benefits may pale 
in comparison to the extremely visible and quantifiably high costs of doing 
research. However, if another nation has invested in research and as a result has 
a major technical and competitive advantage, the costs of research not done 
become large and obvious. Currently, intellectual property protection strategies 
have inadequately accounted for the value of basic research.
The success, not only of our research enterprise per se, but also of our 
improvement of quality of life, has stemmed in large part from the traditional, 
unfettered pursuit of basic knowledge that has been the hallmark of our 
universities. With the decline in public spending and the increasing focus of 
the private sector upon short-term results, we are in danger of failing to build 
the foundation for discoveries in the long term. The problem is exacerbated by 
the constraints placed upon academic researchers by current interpretations of 
intellectual property protection. When we restrict the ability of the not-for- 
profit research community to take findings and push them to new discoveries 
and when we create costs of doing research that are prohibitive, we hinder the 
innovation that has served this country well — innovation that we need more 
than ever before.
Needfora  ResearchExemptionforNotIorProfitResearch
In recent years, university professors have been surprised to find themselves 
restricted by copyright and patent laws that had not been defined or enforced in 
past decades. In practice, university researchers have often assumed that they 
could operate under a research exemption, not subject to the same constraints 
as industry, because they were supported by public funds and worked for not- 
for-profit or state-supported institutions. Recent rulings, however, have made it 
clear that these assumptions were not correct. Universities are subject to many 
of the same restrictions as any industrial organization. In contrast to the 
currently held belief of most university faculty, there is no general research 
exemption for university-based research.
Many scientists have the false perception that there is a general exemption for 
university or government-based research if it is purely philosophical in purpose. 
It is argued that universities have lost the claim to a philosophical exemption
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because they file patents, exercise patent rights, and receive fees for licensing 
and royalties. A different basis for exemption based on the sovereign rights of 
the states and their agency to enjoy immunity from patent infringement, has 
been ended by an amendment of the Copyright Act of 1990 that put the states 
on the same footing as other defendants. The federal government, however, has 
not lost these rights of sovereignty and could expand the scope of an exemp-
tion. Federal employees and recipients of federal grants could be considered 
agents of the government for such purposes, thus effectively receiving an 
exemption for government-sponsored research.
In conclusion, there is a need to modify patent policy or law in order to 
encourage basic research. The current status of the law and its interpretation is 
unnecessarily restrictive and impedes innovation and discovery. Even though 
universities will continue to play a role in discovering information that will be 
useful to industry, publicly funded basic research should still be distinguished 
from corporate research for profit. It is important that our current intellectual 
resources, the envy of the world, be fostered and maintained for future 
commercial development and for the well-being of our citizens.
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